Skip to content

Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula

Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02450643
Enrollment
83
Registered
2015-05-21
Start date
2015-04-30
Completion date
2017-06-30
Last updated
2017-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cow's Milk Allergy

Brief summary

Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges (DBPCFC) of 2 extensively hydrolyzed formulas in random order. If both food challenges are passed, subjects will be asked to consume the Test formula in an at-home open challenge for 7 days.

Interventions

extensively hydrolyzed formula made with a new enzyme

commercially available extensively hydrolyzed formula

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Months to 4 Years
Healthy volunteers
No

Inclusion criteria

* Born at term (\>36 weeks gestation) * 2 months to \<4 years of age at enrollment * Documented CMA within 6 months prior to enrollment * Otherwise healthy * Having obtained his/her legal representative's informed consent

Exclusion criteria

* Children consuming mother's milk at the time of inclusion and during the trial * Any chromosomal or major congenital anomalies * Chronic medical diseases (ie seizure disorders, chronic lung disease, heart problems (heart murmurs okay)) * Immunodeficiency * Receiving free amino acid formula * Subject who in the Investigator's assessment cannot be expected to adhere to the study protocol * Currently participating in another clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
allergic reaction2 hours post-DBPCFCnumber of children who react during a DBPCFC to either formula

Secondary

MeasureTime frameDescription
stool characteristics1 weekstool descriptors as collected on daily diaries
formula intake1 weekamount of formula ingested as collected on daily diaries
adverse events1 weekany adverse event reported by caregivers

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026